Laurus Labs Limited Stock Price Today (NSE: LAURUSLABS)
Fundamental Score
Laurus Labs Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Laurus Labs Limited share price today is ₹2002.50, down 0.50% on NSE/BSE as of 22 October 2026. Laurus Labs Limited (LAURUSLABS) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.08L (Cr). The 52-week high for LAURUSLABS share price is ₹2089.00 and the 52-week low is ₹902.35. At a P/E ratio of 98.84x, LAURUSLABS is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 18.19% and a debt-to-equity ratio of 0.45.
Laurus Labs Limited Share Price Chart — NSE/BSE Historical Performance
Laurus Labs Limited share price chart: 8.11% return over the past month. 52-week high ₹2089.00, 52-week low ₹902.35.
Laurus Labs Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2052.90 | ₹2079.80 | ₹1993.40 | ₹2012.50 | 12.76L (Cr) | |
| ₹2060.10 | ₹2089.00 | ₹2052.20 | ₹2069.00 | 11.33L (Cr) | |
| ₹2030.40 | ₹2086.00 | ₹2028.70 | ₹2060.10 | 16.07L (Cr) | |
| ₹2025.00 | ₹2046.30 | ₹2008.00 | ₹2018.50 | 8.59L (Cr) | |
| ₹2049.00 | ₹2057.30 | ₹2019.20 | ₹2036.90 | 13.01L (Cr) | |
| ₹2047.10 | ₹2065.00 | ₹2007.80 | ₹2059.40 | 11.41L (Cr) | |
| ₹2044.10 | ₹2069.20 | ₹2036.10 | ₹2069.20 | 14.17L (Cr) | |
| ₹1997.90 | ₹2048.00 | ₹1988.90 | ₹2036.60 | 13.58L (Cr) | |
| ₹2055.00 | ₹2055.00 | ₹1997.90 | ₹1997.90 | 13.94L (Cr) | |
| ₹2052.00 | ₹2065.20 | ₹2035.60 | ₹2052.80 | 15.00L (Cr) |
Laurus Labs Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1973.60 | ₹2089.00 | ₹1952.10 | ₹2012.50 | +1.97% | |
| ₹1888.90 | ₹2055.30 | ₹1811.70 | ₹1980.00 | +4.82% | |
| ₹1821.00 | ₹1949.00 | ₹1769.40 | ₹1915.00 | +5.16% | |
| ₹1525.00 | ₹1826.60 | ₹1448.20 | ₹1816.20 | +19.10% | |
| ₹1372.40 | ₹1531.20 | ₹1342.90 | ₹1517.40 | +10.57% | |
| ₹1100.95 | ₹1393.40 | ₹1100.95 | ₹1362.00 | +23.71% | |
| ₹1020.10 | ₹1144.85 | ₹994.25 | ₹1100.95 | +7.93% | |
| ₹1030.00 | ₹1073.90 | ₹936.30 | ₹992.70 | -3.62% | |
| ₹918.85 | ₹1103.55 | ₹917.95 | ₹1075.80 | +17.08% | |
| ₹1108.00 | ₹1141.00 | ₹951.80 | ₹965.00 | -12.91% | |
| ₹1035.00 | ₹1119.00 | ₹985.90 | ₹1108.00 | +7.05% | |
| ₹957.95 | ₹1033.50 | ₹955.70 | ₹1031.35 | +7.66% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Laurus Labs Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Laurus Labs Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LAURUSLABS across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (18.19%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.35%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (23.14%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (125.49%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (29.10%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (7.92x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹539.58 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 37.64%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 98.84x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (20.41x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-2.15% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-1.89% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Low Promoter Commitment (27.47%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Laurus Labs Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Laurus Labs Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Laurus Labs LimitedLaurus Labs Lim...Selected✓ LAURUSLABS • 540222 | 53.5/100 | ₹2002.50₹2003 | ₹108185.06₹108185.06 | 98.84Average 98.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 72.9/100 | ₹1758.80₹1759 | ₹421988.88₹421988.88 | 34.90Average 34.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 67.2/100 | ₹9144.50₹9145 | ₹242329.25₹242329.25 | 82.97Average 83.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 54.8/100 | ₹4558.90₹4559 | ₹154300.53₹154300.53 | 72.83Average 72.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 71.6/100 | ₹1123.00₹1123 | ₹112075.40₹112075.40 | 25.03Average 25.0 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 35.2/100 | ₹1325.10₹1325 | ₹107048.20₹107048.20 | 31.75Average 31.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 36.5/100 | ₹1233.00₹1233 | ₹102955.50₹102955.50 | 31.87Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1666.90₹1667 | ₹95913.43₹95913.43 | 26.05Average 26.0 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 59.7/100 | ₹2275.50₹2276 | ₹93978.15₹93978.15 | 45.98Average 46.0 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 77.1/100 | ₹1961.60₹1962 | ₹89694.16₹89694.16 | 16.21Average 16.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Glenmark Pharmaceuticals LimitedGlenmark Pharma... GLENMARK • 532296 | 63.9/100 | ₹2226.70₹2227 | ₹62837.47₹62837.47 | 34.95Average 35.0 Average | 0.00%Poor 0.00% Poor | 18.58%Good 18.58% Good | 0.00Excellent 0.0 Excellent | 25.68%Excellent 25.68% Excellent | 9.19%Good 9.19% Good | 0.11% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price421988.88 Cr
- Divi's Laboratories Limited share price242329.25 Cr
- Torrent Pharmaceuticals Limited share price154300.53 Cr
- Zydus Lifesciences Limited share price112075.40 Cr
- Cipla Limited share price107048.20 Cr
Laurus Labs Limited PE Ratio History
Historical price-to-earnings ratio for LAURUSLABS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹6.64 | ₹1108.00 | 166.9x |
| FY 2024 | ₹2.97 | ₹602.70 | 202.9x |
| FY 2023 | ₹14.64 | ₹430.20 | 29.4x |
| FY 2022 | ₹15.35 | ₹375.25 | 24.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Laurus Labs Limited Dividend History
Annual cash dividends paid by LAURUSLABS — dividend yield 0.13%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹43.13 Cr |
| FY 2024 | ₹86.18 Cr |
| FY 2023 | ₹107.47 Cr |
| FY 2022 | ₹85.86 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Laurus Labs Limited Quarterly Performance
Latest quarterly metrics for LAURUSLABS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
29.10%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
125.49%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
7.19%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-1.89%
Compounded annual net profit growth over 5 years
Laurus Labs Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LAURUSLABS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Laurus Labs Limited Financial Statements
Annual income statement, balance sheet and cash flow for Laurus Labs Limited (LAURUSLABS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Laurus Labs Limited
About LAURUSLABS (Laurus Labs Limited)
Laurus Labs Ltd is a dynamic pharmaceutical company forging a path in the global healthcare landscape. With a strong foundation in API manufacturing, Laurus Labs has strategically ...expanded its capabilities to encompass finished dosage formulations, catering to a diverse range of therapeutic areas. This vertically integrated approach allows for greater control over the entire drug development and manufacturing process, ensuring quality and efficiency. Beyond its core API and formulation businesses, Laurus Labs is actively engaged in research and development, investing in cutting-edge technologies and innovative processes to drive future growth. They are emerging as a solutions provider for the pharmaceutical industry, focused on delivering value and making a difference in the lives of patients worldwide. The company's robust portfolio caters to key global health concerns. Laurus Labs develops APIs and formulations across therapeutic segments like anti-retrovirals, crucial in the fight against HIV/AIDS. In addition, they focus on addressing the growing prevalence of conditions like diabetes and cardiovascular diseases, while also developing solutions for respiratory ailments and ophthalmic disorders. Laurus Labs has also ventured into the complex field of oncology, and has added gastroenterology and hepatitis C therapeutic areas, demonstrating their commitment to providing solutions to a diverse spectrum of medical needs. This strategic diversification allows Laurus Labs to mitigate risk and capitalize on emerging opportunities in the pharmaceutical market. Beyond pharmaceuticals, Laurus Labs has expanded its portfolio, exploring opportunities in biotechnology. The company provides services tailored to support industries in the nutraceutical and dietary supplement segments. This includes developing solutions for alternative food applications, reflecting the company's commitment to innovation and diversification. By harnessing its biotechnology capabilities, Laurus Labs has broadened its market reach and expanded its scope to cater to the rapidly evolving needs of the health and wellness industry. This strategic move positions Laurus Labs at the forefront of innovation, enabling the company to capitalize on emerging opportunities and drive future growth.
Company Details
Key Leadership
LAURUSLABS Share Price: Frequently Asked Questions
What is the current share price of Laurus Labs Limited?
Laurus Labs Limited (LAURUSLABS) trades at ₹2002.50 on NSE and BSE. Market cap ₹1.08L (Cr). Educational data only.
What is the P/E ratio of Laurus Labs Limited?
Laurus Labs Limited has a P/E of 98.84x vs industry average 34.89x.
What is the Bull Run score for Laurus Labs Limited?
Laurus Labs Limited has a Bull Run score of 53.5/100 based on 25+ financial parameters.
Does Laurus Labs Limited pay dividends?
Laurus Labs Limited has a dividend yield of 0.13%. Past dividends don't guarantee future payments.
What is the ROE of Laurus Labs Limited?
Laurus Labs Limited has ROE of 18.19%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Laurus Labs Limited?
Laurus Labs Limited has debt-to-equity of 0.45.
Is Laurus Labs Limited a good investment?
Bull Run gives Laurus Labs Limited a score of 53.5/100. This is not investment advice — consult a SEBI-registered advisor.